TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02680951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 8mg/m2/dose intravenous infusion over 15 minutes, once daily, on days 3 to 5, total 3 doses~Participants with body weight less than 12Kg, the idarubicin dose will be corrected as follows: \[weight (Kg) x dose (per m2)\] divided by 30

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) cytarabine
Description: Given intrathecally to all participants on day 1 of course 1 and 2. Omit on day 1 of course 1 if participant received IT therapy within 7 days prior to study enrollment. Intrathecal chemotherapy may be given during the end of course 1 disease evaluation (spinal fluid and bone marrow aspiration) and may be repeated every 7 days with bone marrow evaluations per institutional preference.~Cytarabine dose defined by age:~* 30 mg for patients age 1 - 1.99~* 50 mg for patients age 2 - 2.99~* 70 mg for patients ≥3 years of age~The participant may receive intrathecal triple therapy (ITT) if persistent blasts are present in the cerebral spinal fluid (CSF) based on the treating physician's clinical judgment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) cytarabine
Description: Given intrathecally to all participants on day 1 of course 1 and 2. Omit on day 1 of course 1 if participant received IT therapy within 7 days prior to study enrollment. Intrathecal chemotherapy may be given during the end of course 1 disease evaluation (spinal fluid and bone marrow aspiration) and may be repeated every 7 days with bone marrow evaluations per institutional preference.~Cytarabine dose defined by age:~* 30 mg for patients age 1 - 1.99~* 50 mg for patients age 2 - 2.99~* 70 mg for patients ≥3 years of age~The participant may receive intrathecal triple therapy (ITT) if persistent blasts are present in the cerebral spinal fluid (CSF) based on the treating physician's clinical judgment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) cytarabine
Description: Given intrathecally to all participants on day 1 of course 1 and 2. Omit on day 1 of course 1 if participant received IT therapy within 7 days prior to study enrollment. Intrathecal chemotherapy may be given during the end of course 1 disease evaluation (spinal fluid and bone marrow aspiration) and may be repeated every 7 days with bone marrow evaluations per institutional preference.~Cytarabine dose defined by age:~* 30 mg for patients age 1 - 1.99~* 50 mg for patients age 2 - 2.99~* 70 mg for patients ≥3 years of age~The participant may receive intrathecal triple therapy (ITT) if persistent blasts are present in the cerebral spinal fluid (CSF) based on the treating physician's clinical judgment.
Study: NCT01392963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A neurotoxin complex
Description: 29-40 U injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A neurotoxin complex
Description: 29-40 U injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 29-40 U 0.9% NaCl injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 29-40 U 0.9% NaCl injection
Study: NCT05861297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients were initiated with High Dose-Dexamethasone with a dose of 40 mg/m2 daily for four days per week immediately after the diagnosis of ITP for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone and Azathioprine
Description: the second group received 20 mg of Prednisolone three times daily and 1 mg/kg of oral Azathioprine once daily for two weeks, then tapering the Prednisolone dose through the subsequent weeks (6 weeks). While continuing treatment with Azathioprine for a total of six months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: The third group received 500 mg/m2 intravenously of Rituximab once weekly for one month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: The fourth group received 50 mg of Eltrombopag four hours before or after meals as oral daily doses for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: The fifth group received 3μg/kg subcutaneous injection of Romiplostim once a week for 6 months
Study: NCT02688660

Intervention type: OTHER
Intervention: MRI Scans

Intervention type: OTHER
Intervention: MRI Scans
Study: NCT02289443

Intervention type: OTHER
Intervention: complete denture
Description: Comparison of different procedures

Intervention type: OTHER
Intervention: complete denture
Description: Comparison of different procedures
Study: NCT01524978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Escalating doses administered on Day 1 and then once weekly by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: Escalating doses given orally twice a day starting on Day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: 960 mg vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: 960 mg vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: 960 mg vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: 960 mg vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: 960 mg vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: 960 mg vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.
Study: NCT01026220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given IV
Study: NCT04996459

Intervention type: DRUG
Intervention: Tislelizumab
Description: Tislelizumab 200mg iv q3w
Study: NCT01026220

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study: NCT03762798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Bridge
Description: The Bridge (Also known as NSS-2) is a percutaneous, auricular field stimulator developed to alleviate pain through stimulation of peripheral cranial neurovascular bundles in the external ear that could potentially gain access to brain areas involved in fear, pain and nociception. After five days, the subject will return to the clinic for device removal and disposal.
Study: NCT03744520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Local anesthetic infiltration is applied between the erector spinae muscle fascia and transverse process.
Study: NCT03011307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: spinal injection of oxytocin
Study: NCT03579173

Intervention type: DIAGNOSTIC_TEST
Intervention: Infant PFT
Description: Assessed through the raised volume rapid thoracoabdominal compression technique and plethysmography

Intervention type: DIAGNOSTIC_TEST
Intervention: Infant PFT
Description: Assessed through the raised volume rapid thoracoabdominal compression technique and plethysmography

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Clearance Index
Description: The Lung Clearance Index is derived from the Multiple Breath Washout test. It is the cumulative exhaled volume (the volume of gas needed to wash out resident gas mixture out of the lungs) divided by the FRC. The FRC is the amount of air left in the lungs after normal exhalation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Passive tidal breathing
Description: During quiet sleep, tidal breathing flow-volume curves are obtained. The tPEF/tE is calculated by taking the time it takes to reach peak expiratory flow divided by the total peak expiratory time.
Study: NCT02424045

Intervention type: DRUG
Group type: OTHER
Intervention: BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)
Description: All patients are scheduled to receive 2 cycles of three-weekly BCD. After 2 cycles of BCD, if the patients with complete remission (CR) or partial remission (PR) would be eligible for autologous stem cell transplantation (ASCT), stem cell collection after 3rd cycle of BCD and high dose chemotherapy and ASCT will be conducted. While ineligible patients to ASCT with non-progressive disease after 2 cycles of BCD, will be given 4 additional courses of the BCD regimen.
Study: NCT03650790

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood test
Description: For serum analysis, approximately 2 cc antecubital vein venous blood serum will be taken from each patient to be studied for CTRP9 Level analysis. Adult blood will be centrifuged at 4000 rpm for 10 minutes to separate greenhouses. The obtained serum samples will be stored at -80 ° C until analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood test
Description: For serum analysis, approximately 2 cc antecubital vein venous blood serum will be taken from each patient to be studied for CTRP9 Level analysis. Adult blood will be centrifuged at 4000 rpm for 10 minutes to separate greenhouses. The obtained serum samples will be stored at -80 ° C until analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood test
Description: For serum analysis, approximately 2 cc antecubital vein venous blood serum will be taken from each patient to be studied for CTRP9 Level analysis. Adult blood will be centrifuged at 4000 rpm for 10 minutes to separate greenhouses. The obtained serum samples will be stored at -80 ° C until analysis.
Study: NCT01555489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: 3x per week
Study: NCT00351962

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiotherapy
Study: NCT01760590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Manipulation
Description: A grade 5 thrust to the thoracic spine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobilization
Description: A grade 1-4 mobilization directed at thoracic spine
Study: NCT01344720

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoricoxib
Description: At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 1 non-responders will receive an increase in monotherapy from etoricoxib 30mg to eterocoxib 60mg/die.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone
Description: At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 2 non-responders will receive in addition to etoricoxib 30mg/day a dose of oxycodone CR 5mg q12hr (dose of 5mg tablet is available in Italy).
Study: NCT01846650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine tablets
Description: Single oral Capecitabine tablets 2000mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELODA
Description: Single oral XELODA 2000mg qd
Study: NCT02562807

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-303 18mg single-dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAS-303 18mg single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 18mg single-dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 18mg single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-303 9mg single-dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAS-303 9mg single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 9mg single-dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 9mg single-dose
Study: NCT01270256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo delivered intranasally via NasoNeb nebulizer once daily
Study: NCT02068872

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy
Description: To assess the safety, tolerability and feasibility of sleeve gastrectomy in the perioperative period following liver transplantation in obese (BMI of \> 40 or \> 35 kg/m2 in the presence of at least one major obesity related co-morbidities (e.g. type 2 diabetes, hypertension, sleep apnea, heart disease, etc) adult subjects aged 18-75 years of age.
Study: NCT03974373

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BFP removal
Description: The surgical procedure was performed using the technique with intrabuccal access, already consecrated in the literature (Materasso 2006). The Bichat fat ball access was made by means of a small incision no more than 3 mm in length in the soft tissue located in the lower aspect of the zygomatic counterfoot, taking care to visualize and protect with the retractor the Stensen's conduit. With the aid of blunt-tipped or hemostatic scissors dissection was performed, taking care to preserve the membrane surrounding the ball of fat. After removal of one side, pressure was removed to remove air and the procedure was started on the opposite side, after the removal of the two sides was realized simple suture with silk thread. There were no formal indications for sending the samples for anatomic and / or histological examination.
Study: NCT03040986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Sulfate
Description: Given by mouth (PO)
Study: NCT02887547

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: micro-osteoperforation
Study: NCT04421209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hcl 40mg Tab
Description: 40mg PO BID for the three days prior to surgery, 40mg PO BID the day of surgery and on post-op days 1 and 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo tablets administered with the same schedule of Propranolol tablets
Study: NCT00786344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Redesign
Description: For a six-month period, each elder participated in weekly 2-hour sessions involving groups of size 8-10, and also received up to 10 hours of individualized treatment over this time period.~Modular treatment units included the following content areas: (1) Introduction to the Power of Activity; (2) Aging, Health, and Activity; (3) Transportation; (4) Safety; (5) Social Relationships; (6) Cultural Awareness; (7) Finances; and (8) Integrative Summary: Lifestyle Redesign Notebook. The methods of program delivery consisted of didactic presentation, peer exchange, direct experience, and personal exploration. Treatment materials were translated into Spanish and culturally adapted for approximately 15% of the subjects.
Study: NCT03274648

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral butyrate
Description: Patients follow the habitual diet supplemented with 2.4g/day of oral butyrate
Study: NCT01192828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taurine
Description: Take Taurine for 4 1/2 days, two doses per day
Study: NCT00328250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment (CBT) delivered over the Internet
Description: CBT delivered over the Internet for insomnia targets maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems. Treatment includes through educational, behavioral, and cognitive strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral treatment (CBT) delivered over the Internet
Description: CBT delivered over the Internet for insomnia targets maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems. Treatment includes through educational, behavioral, and cognitive strategies.
Study: NCT03822000

Intervention type: OTHER
Intervention: Survival
Description: Elderly patients with fall-induced femoral fracture who were survived.

Intervention type: OTHER
Intervention: Death
Description: Elderly patients with fall-induced femoral fracture who were dead.
Study: NCT03011307

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: spinal injection of placebo
Study: NCT01695694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: supporting positive and healthy relationships

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: community support group
Study: NCT02157155

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS
Description: LPS is endotoxin from gram negative bacteria. It is used scientifically to mimic infection lasting 4-8 hours.
Study: NCT03099876

Intervention type: PROCEDURE
Intervention: treatment period
Description: 7 days treatment or 10 days treatment

Intervention type: PROCEDURE
Intervention: treatment period
Description: 7 days treatment or 10 days treatment
Study: NCT02275481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
Study: NCT05083793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: The effect of pregabalin on post-operative pain

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will receive placebo one hour before operation
Study: NCT01352988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fumaric acid esters
Description: Starting from 1 tablet Fumaderm® initial per day, with titration up to 6 tablets Fumaderm® per day; in case of side effects, the dose will be adapted to the highest tolerable levels
Study: NCT02283710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline 600 mg BD

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: obtaining ideal body weight by calorie restriction diet and programmed physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: obtaining ideal body weight by calorie restriction diet and programmed physical activity.
Study: NCT03543592

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3 dimensional ultrasonography and Doppler
Description: Three-Dimensional images will be recorded. The volumes will be generated by the automatic rotation of the mechanical transducer 360 degrees. Visualization of the endometrium and myometrium in the three planes will be done to detect endometrial cavity and any lesions. The power Doppler gate will be activated for blood flow mapping of the endometrium and endometrial-myometrial interface (sub-endometrial area). The pulsed Doppler sample volume will be activated to obtain a flow velocity waveform (FVW). Vascularization index (VI), flow index (FI) and vascularization-flow index (VFI) will be automatically calculated from three consecutive FVWs.
Study: NCT03274648

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Description: Patients follow a vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Habitual diet
Description: Patients follow the habitual diet